Related Experiment Videos
Insights
Enlarged total gastrectomy offers curative potential for early-stage (I and II) cardial adenocarcinoma in suitable patients. This surgical approach shows no survival benefit for advanced stages (III and IV) of the disease.
Area of Science:
- Oncology
- Surgical Gastroenterology
Context:
- Cardial adenocarcinoma presents a significant challenge in upper gastrointestinal cancer treatment.
- Surgical intervention is a primary modality for potentially curative treatment.
Purpose:
- To evaluate the efficacy of enlarged total gastrectomy in treating cardial adenocarcinoma.
- To determine the optimal stage for employing this surgical approach.
Summary:
- Retrospective analysis of 38 patients indicates enlarged total gastrectomy is effective for early-stage (I and II) cardial adenocarcinoma in patients with good general health.
- The procedure does not offer survival advantages for Stage III or IV cardial adenocarcinoma, with limited survival rates regardless of treatment.
Impact:
- This study suggests that enlarged total gastrectomy can be a curative option for specific patient cohorts with cardial adenocarcinoma.
- It highlights the importance of stage-specific treatment strategies in managing cardial adenocarcinoma, guiding clinical decision-making.
Abstract:
The extensed total gastrectomy of principle represents a new hope in the surgical treatment of the cardial adenocarcinoma. On the basis of a retrospective study of 38 patients (30 men and 8 women) we think that for patients in good general condition and for stades I and II, the enlarged total gastrectomy represents the only treatment with curative aiming. As for stade III and a fortiori stade IV, there is no advantage to use the enlarged total gastrectomy. For stade III, survival is inferior to 10 months, whatever the type of operation used, and for stade IV survival is inferior to 3 months, whatever the treatment.